Drugs / Telacebec
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02858973 | Aug 2016 → May 2018 | — | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02530710 | Aug 2015 → Jan 2016 | — | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06481163 | Jul 2024 → Dec 2027 expected | Buruli ulcer disease | Barwon Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04847583 | Jul 2021 → Feb 2022 | COVID-19 | Qurient Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT03563599 | Jul 2018 → Sep 2019 | tuberculosis | Qurient Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telacebec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481163 ↗ |
| Known as | Q203 | “A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients” NCT04847583 ↗ |
| Modality | Small molecule | — CHEMBL3298910 ↗ |
| Route | Oral | “administered Orally” NCT02858973 ↗ |